Fei Duan

Background

About Fei Duan

As the Co Director of Human Immune Monitoring, Immunotherapy Platform (IMT) at MD Anderson Cancer Center, I lead a team of researchers and clinicians who are dedicated to understanding and improving the immune system's response to cancer. With over 7 years of experience in this role, I have co-led multiple preclinical and clinical trials that leverage cutting-edge technologies and novel combinations of immune checkpoint inhibitors, such as Ipilimumab, Tremelimumab, nivolumab, and relatlimab to treat various types of tumors and enhance patient outcomes. My mission is to translate the latest advances in immunology into effective and personalized cancer therapies that can benefit patients across the world. I have built strong internal and external collaborations and strategic partnerships with academic institutions, biotechnology companies, and pharmaceutical organizations to accelerate the development and validation of translational biomarkers and immunotherapeutic strategies. I have also contributed to the field of cancer immunology with multiple publications, patents, and presentations, sharing my expertise and insights with the scientific community and the public.